Identification and characterization of stromal-like cells with CD207+/low CD1a+/low phenotype derived from histiocytic lesions – a perspective in vitro model for drug testing

Table 1 Patient’s clinical characteristics

Patient code in the clinical study	Gender/Age	Diagnosis	Histiocytosis type	Treatment	Mutation in the pathological tissue	Mutation in the blood	Outcome	Name of the cell line
002	F/5y	LCH	Multisystem (skin, bone) R0 plus; relapse, neurodegenerative disease	CHT, TKI	BRAF	BRAF	AWD	RAB-1
014	F/1y	Non-LCH	Single sytem (skin)	None	None	None	CR	HAN-1
007	M/17y	LCH	Single system (bone), multifocal, R0 minus; relapse	CHT	BRAF	None	CR	CHR-1

F female, M male, LCH Langerhans cell histiocytosis, R0 risk organ, CHT chemotherapy, TKI tyrosine kinase inhibitor, AWD alive with disease, CR complete remission

ISSN: 1471-2407